EN DE
Watch Pyxis Oncology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pyxis Oncology Inc (PYXS) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Pyxis Oncology Inc stock $1.34, price $1.58, that is 15.2% below the price, quality 31 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US7473241013

PO Pyxis Oncology Inc logo Thin data Nov 10, 2026

Pyxis Oncology Inc

PYXS · US

Expensive (fair value 15% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Price moving sideways (no uptrend) 
Insiders sold $107,100 (6M) 
Fair value $1.34 · Overvalued 
Quality 31/100 
Weak Growth (revenue YoY −14.2 %/yr in USD) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 10/100 · thin data
Recent news very negative 
Thin data 
Estimate
Watch Pyxis Oncology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.64 $0.8773 Fair Value $1.34 Oct 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.8773 – $13.64 · fair‑value band $1.00 – $1.67 · the $1.58 price screens above the $1.34 fair value. As of Nov 10, 2026.

Follow Pyxis Oncology in your weekly email

Every Wednesday you see whether Pyxis Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.

Show moreShow less

Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.

It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.

Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Stock analysis

Pyxis Oncology Inc (PYXS) currently trades at $1.58, while our estimate is $1.34, 15% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.00 (bear) to $1.67 (bull), the price of $1.58 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Pyxis Oncology Inc reported revenue of $13.9M in FY2025 versus $0 in FY2021. Reported net income was −$79.6M in FY2025.

Key figures

Market cap $189M Micro · P/S ratio 18.0 · EPS (TTM) $−1.27 · Return on equity −179% · Return on assets (EBIT) −56.0% (5-year average) · Operating margin −813% · Revenue (TTM) $11.0M · Free cash flow −$63.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −15%, PYXS screens richer than that median.

Fair Value

Bear $1.00 Fair Value $1.34 Bull $1.67
Price $1.58 · Downside -15.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 25
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $107,100 and none bought.

  • BuyGordonMD Global Investments LP10% owner5,517,000 shares at ?Oct 1, 2026
  • SaleJakob DupontDirector35,000 shares at $3.06$107,100Jun 30, 202610b5-1 plan

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PYXS screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (70 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Pyxis Oncology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Below median
Fair Value upside −15.2% · Above median
Profitability
Return on assets −87.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.53× · Pricier than median
P/S (12 months) 17.10× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs PYXS
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs PYXS
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs PYXS
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs PYXS
argenx SE ARGX $960.04 $908.40 −5% vs PYXS
CSL Limited CSL A$202.52 A$185.51 −8% vs PYXS
Moderna, Inc MRNA $223.37 $139.99 −37% vs PYXS
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs PYXS
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs PYXS
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs PYXS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pyxis Oncology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pyxis Oncology Inc Fair Value". https://www.fairvalue-calculator.com/stock/PYXS

Frequently asked questions

Is Pyxis Oncology Inc (PYXS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.34 versus a price of $1.58, about 15% lower (overvalued).
What is the fair value of PYXS?
Our estimate for Pyxis Oncology Inc is $1.34 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.58.
What is the quality score of PYXS?
Pyxis Oncology Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pyxis Oncology Inc (PYXS)?
Our calculated price target is the estimate of $1.34 (as of Nov 10, 2026). Cautious scenario $1.00, optimistic scenario $1.67. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pyxis Oncology Inc stock forecast for 2026?
Our estimate puts fair value at $1.34, about 15% lower versus a price of $1.58 (overvalued). Cautious scenario $1.00, optimistic scenario $1.67. The calculation is refreshed regularly with new filings.
What is the revenue of Pyxis Oncology Inc (PYXS)?
Pyxis Oncology Inc reported trailing-twelve-month revenue of about $11.0M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pyxis Oncology Inc (PYXS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pyxis Oncology Inc it is $1.34 per share (as of Nov 10, 2026), against a price of $1.58.
Is Pyxis Oncology Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PYXS trades above its calculated fair value: price $1.58, fair value $1.34, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PYXS?
No. The price is what the market pays today ($1.58); the fair value is what the company's own numbers justify ($1.34). For Pyxis Oncology Inc the two are $0.2400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pyxis Oncology Inc worth?
The market values Pyxis Oncology Inc at about $189M (market capitalisation, as of Nov 10, 2026). Per share that is $1.58; our models calculate a fair value of $1.34 per share.
What do the bullish and bearish scenarios say about PYXS?
Our models span a range for Pyxis Oncology Inc: cautious scenario $1.00, base $1.34, optimistic $1.67 per share (as of Nov 10, 2026, price $1.58). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pyxis Oncology Inc (PYXS)?
Balance-sheet figures for Pyxis Oncology Inc (as of Nov 10, 2026): return on equity −179.1%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is PYXS from its 52-week high?
Pyxis Oncology Inc trades at $1.58, about 70% below its 52-week high of $5.34 and 49% above the low of $1.06 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $1.34 is for.
Which stocks are comparable to Pyxis Oncology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pyxis Oncology Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.58, calculated fair value $1.34 (−15%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Pyxis Oncology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pyxis Oncology Inc (PYXS)?
The closing price on Nov 13, 2026 was $1.58. Our estimate is $1.34, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pyxis Oncology Inc right now?
Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pyxis Oncology Inc

How large is the market capitalisation of Pyxis Oncology Inc (PYXS)?
The market capitalisation of Pyxis Oncology Inc is $189M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pyxis Oncology Inc (PYXS)?
The price-to-sales ratio of Pyxis Oncology Inc is 18.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pyxis Oncology Inc (PYXS)?
Earnings per share at Pyxis Oncology Inc are $−1.27. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pyxis Oncology Inc (PYXS)?
The return on equity (ROE) of Pyxis Oncology Inc is −179% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pyxis Oncology Inc (PYXS)?
On an EBIT basis the return on assets of Pyxis Oncology Inc is −56.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pyxis Oncology Inc (PYXS)?
The operating margin of Pyxis Oncology Inc is −813% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Pyxis Oncology Inc (PYXS) generate?
The free cash flow of Pyxis Oncology Inc is −$63.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pyxis Oncology Inc (PYXS) carry?
The net debt of Pyxis Oncology Inc is $3.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pyxis Oncology Inc in the live analysis

One click puts Pyxis Oncology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.